PALO ALTO, Calif.–(BUSINESS WIRE)–BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company
focused on genetic diseases, today announced that it has filed a
registration statement on Form S-1 with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed initial public offering of
shares of its common stock. The number of shares to be offered and the
price range for the proposed offering have not yet been determined.
BridgeBio has applied to list its common stock on the Nasdaq Global
Market under the symbol “BBIO.”
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC, SVB
Leerink LLC, KKR Capital Markets LLC, Piper Jaffray & Co., Mizuho
Securities USA LLC, BMO Capital Markets Corp. and Raymond James &
Associates, Inc. will act as book-running managers for the proposed
The proposed offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to the proposed offering may be
obtained, when available, for free by visiting EDGAR on the SEC’s
website at www.sec.gov.
Alternatively, copies of the prospectus, when available, may be obtained
for free from the offices of J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, telephone: 1-866-803-9204 or by emailing [email protected];
Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street,
New York, NY 10282, telephone: 1-866-471-2526 or by emailing [email protected];
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, telephone:
1-877-547-6340, or by emailing [email protected];
or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, Massachusetts 01220, telephone: 1-800-808-7525, ext.
6132, or by emailing [email protected].
The offering is subject to market and other conditions, and there can be
no assurance as to whether or when the offering may be completed.
A registration statement relating to these securities has been filed
with the SEC but has not yet become effective. These securities may not
be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
About BridgeBio Pharma
BridgeBio is a team of experienced drug discoverers, developers and
innovators working to create life-altering medicines that target
well-characterized genetic diseases at their source. BridgeBio was
founded in 2015 to identify and advance transformative medicines to
treat patients who suffer from Mendelian diseases, which are diseases
that arise from defects in a single gene, and cancers with clear genetic
drivers. BridgeBio’s pipeline of over 15 development programs includes
product candidates ranging from early discovery to late-stage